CELL AND GENE THERAPY

Enzychem Lifesciences Announces Formation of Corporate Advisory Committee

Enzychem Lifesciences | March 03, 2022

Enzychem Lifesciences a clinical-stage biotechnology company, announced today the formation of its Corporate Advisory Committee. Composed of four eminent physicians, its mission is to support and guide corporate activities including technology transfer for its lead compound, EC-18, seeking strategic partnerships, and preparing U.S. phase 3 clinical trials to successfully commercialize EC-18.

After the completion of its phase 2 U.S. clinical trial with EC-18 in Chemoradiation–induced Oral Mucositis (CRIOM), Enzychem is actively negotiating licensing deals with several partnering candidates while also preparing a phase 3 trial under a US FDA IND. To reinforce such corporate initiatives, and to start supporting the company’s next stage activities, Enzychem has formed the Corporate Advisory Committee.

Enzychem Lifesciences recognizes the need for engagement of key opinion leaders at an earlier stage in the process of developing new therapeutics for a large population with high unmet needs such as Chemoradiation-induced Oral Mucositis (CRIOM). Enzychem is proactively bringing more experts to the company to strengthen its new drug development capabilities. The newly appointed corporate advisors will actively influence the development of strong business strategies to successfully meet corporate objectives.

The four physicians appointed are Dr. Alexander Fleming, a former FDA reviewer and supervisory medical officer, as head of the metabolic group, Dr. Frank Castellana, a market value assessment expert, Dr. Joe McMenamin, a health lawyer, and Dr. Richard Hamrick, a former healthcare provider executive. Based on their extensive experience, the corporate advisors will assist Enzychem in accomplishing its business milestones.

For two years, until 2018, Dr. Fleming served as Enzychem’s Chief Technology Officer (CTO). During his term, Dr. Fleming had recommended CRIOM as the lead indication for EC-18 and introduced Dr. Steve Sonis of Harvard School of Dental Medicine as Enzychem’s key advisor for the U.S. phase 2 CRIOM Study.

Enzychem Lifesciences  is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies for patients with unmet medical needs in oncology, metabolic, and inflammatory diseases. Founded in 1999, the company’s lead compound, EC-18, acts as an immunomodulator, facilitating the resolution of inflammation and the early return to immune homeostasis. Enzychem is headquartered in South Korea, with an office in the United States. 

Spotlight

Animation video about the identification and isolation of the gene of interest.


Other News
MEDICAL

ImmunoTek Bio Centers First to Launch VeinViewer® Technology for Plasma Donations

ImmunoTek Bio Centers | April 27, 2022

Donating plasma is now easier, thanks to a smart new tool allowing technicians to see the map of veins inside a plasma donor's arm. ImmunoTek Bio Centers proudly announces its two divisions – ImmunoTek Plasma and Freedom Plasma – are the first blood plasma collection centers to use this groundbreaking technology. The VeinViewer®, developed by Christie Medical Holdings, has had great success in hospitals and medical clinics, and recently in pilot programs with ImmunoTek. Using the VeinViewer® in a plasma donation setting provides phlebotomists with real-time images of the donor's veins before needle insertion. The VeinViewer® uses direct projection vein illumination to identify vein patterns and display them on a patient's skin. As part of plasma donation, a needle is inserted into the donor's arm to withdraw blood that is then separated into individual parts during a process called plasmapheresis. Being able to easily see where the donor's veins are located helps phlebotomists as they insert the needle to begin the process. Our technicians found that using the VeinViewer® provides a clear look at a donor's veins before the needle is inserted. The ability to see this image increases their accuracy, makes the donation process faster, and reduces the likelihood of reinserting the needle, We are proud to be the first plasma collection company to offer this next-level service for our donors." Blair McKinney, Chief Operating Officer of ImmunoTek Bio Centers. We are delighted ImmunoTek selected Christie's leading vascular visualization technology to aid in establishing a comfortable environment and efficient encounter for donors." Paul Damiani, Christie Medical Holdings, Inc President. ImmunoTek has created an unparalleled donation ambiance and we look forward to integrating the unmatched VeinViewer for an even better donor experience." Lisa Kaufman, Vice President at Christie. The United States provides 2/3 of the world's supply of plasma, which is used to make critical life-saving medicines and plasma-based therapies. Blood plasma is in great demand and the need for it increases 6-8 percent yearly. Increasing plasma donations helps meet the need for plasma around the world. ABOUT IMMUNOTEK BIO CENTERS, LLC ImmunoTek Bio Centers LLC is the fastest-growing independent plasma collection center operator in the United States and is a global leader in developing a reliable plasma supply chain for biotech companies. Since its inception in 2013, ImmunoTek has built and operated more than 50 plasma collection centers, most of which are or are in the process of becoming FDA-licensed and EU-certified, with nearly 40 additional centers in progress. ABOUT CHRISTIE MEDICAL HOLDINGS, INC. Christie Medical Holdings is a medical device manufacturer based in Lake Mary, FL, USA. Our market-leading, VeinViewer® Vision2 and Flex systems, are near-infrared, vascular imaging devices that allow clinicians to clearly see accessible vasculature as a real-time HD image, projected directly on the surface of the patient's skin. Since its invention, VeinViewer has transformed over the years into the current innovative models found in over 50 countries to accurately and safely illuminate veins up to 10 mm deep. It is the only vein finder of its kind that can positively impact the entire Pre-, During- and Post-access procedure through proven clinical and cost-saving results.

Read More

MEDICAL

Ochre Bio Launches ‘Liver ICU’ in the United States to Evaluate Effects of RNA Therapies on Human Liver Performance

Ochre Bio | May 12, 2022

Ochre Bio, a biotech company developing RNA medicines for chronic liver diseases, announced today the launch of their ‘Liver ICU’. Housed in BioLabs@NYULangone, a biopharma incubator in New York City, this research site will evaluate the efficacy of new RNA therapeutics on whole human livers maintained on machines. The use of discarded donor livers for research is expected to enhance timelines and accuracy of liver medicine research by testing interventions directly in human livers maintained under conditions mimicking human physiology. This site is a part of a network of three leading liver perfusion research sites across the US. The other two US research sites are the laboratory of Greg Tietjen, Ph.D at Yale University, a pioneer in the field of ex vivo organ research, and LifeShare of Oklahoma, a leading US organ procurement organization. In addition, Ochre Bio is also announcing a partnership with OrganOx, a company at the forefront of changing the way donor livers are preserved in the critical time between donation and transplantation, and one of the first companies to have a liver perfusion device approved by the FDA. This research will involve hundreds of donor livers being kept alive outside the body for multiple days each. These are donor livers that cannot be used for transplant patients for various reasons, and so would be otherwise discarded. The livers will be maintained in human physiological conditions and used to test therapeutic interventions, with the goal of finding new therapies to improve liver transplant outcomes, in the hopes of thereby increasing the supply of transplantable livers, as well as uncovering insights relevant to a wider set of liver diseases. Greg Tietjen’s research group at Yale and LifeShare of Oklahoma will work with the Ochre research team towards being able to consistently perfuse organs for several days to study the effects of RNA therapy on liver performance. We’re excited to announce this new research site in the US, as well as these partnerships with world leaders in liver perfusion research and transplant medicine, This collaboration to evaluate the effects of RNA therapy directly in human livers preclinically is a step change for liver research, that we hope will lead to treatments for a number of liver diseases, and one day reduce the burden of liver transplantation for patients.” Jack O’Meara, CEO & Co-Founder at Ochre Bio. Thanks to the collaborative efforts of Ochre Bio, OrganOx, Yale University and, LifeShare of Oklahoma, the unique capabilities of the OrganOx metra are enabling multi-day isolated organ perfusion research and facilitating a new and exciting approach to developing novel therapeutics for liver diseases. We look forward to seeing the results of this approach leave research and enter the clinic in the future.” Craig Marshall, CEO, OrganOx. We view this work as an opportunity to honor the profound gift that every donor organ represents. While the organs enrolled in this study may not save the life of one transplant recipient, they have the potential to save hundreds of thousands of lives in the future by enabling breakthrough new therapies from Ochre Bio to treat end stage liver disease.” Gregory Tietjen, Ph.D., Assistant Professor of Transplant Surgery, Yale School of Medicine About Ochre Bio Ochre Bio is a biotechnology company developing RNA therapies for chronic liver diseases. Using a combination of genomic deep phenotyping, precision RNA medicine, and testing in live human donor livers, Ochre is developing therapies for important liver health challenges, from increasing donor liver supply to reducing cirrhosis complications. With laboratories across the UK, Asia and North America, the team has decades of experience leading liver genomics research and bringing advanced therapies to market.

Read More

INDUSTRIAL IMPACT

Element Biosciences Becomes the Newest Member of 10x Genomics’ Compatible Partner Program (CPP) Across Multiple Single Cell Applications

Element Biosciences, Inc. | March 01, 2022

Element Biosciences, Inc., developer of a new and disruptive DNA sequencing platform, announced a partnership with 10x Genomics, a life sciences leader focused on mastering biology to advance human health, that demonstrates the seamless integration of the Element AVITI™ System and 10x Genomics’ single cell technologies. 10x Genomics’ Chromium Single Cell and Visium Spatial platforms enable researchers to examine biology at true resolution, combining hardware, chemistry, and software to give single cell and spatial views of biology at a scale and efficiency that is unprecedented. The combination of the AVITI System’s performance, cost, and flexibility with 10x Genomics’ leading single cell assays provides customers more access and choice for their biological research. “We are excited about the partnership we’ve established with 10x Genomics and our new status as a validated CPP member. As one of the most exciting new areas in NGS, we believe this will help bring 10x Genomics’ and Element Biosciences’ customers together for our combined performance and cost advantages in single cell and spatial analysis.” Shawn Levy, Senior Vice President of Applications and Scientific Affairs, Element Biosciences “At 10x Genomics, part of our commitment to supporting our customers with single cell and spatial analysis is ensuring they have access to advanced sequencing solutions through rigorous validation,” said Brad Crutchfield, Chief Commercial Officer, 10x Genomics. “We are excited to certify Element through our Compatible Partner Program and provide our customers with more ways to adopt single cell and spatial analysis to enhance their research and fuel scientific discoveries.” About 10x Genomics 10x Genomics is a life science technology company building products to interrogate, understand and master biology to advance human health. The company's integrated solutions include instruments, consumables and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. 10x Genomics products have been adopted by researchers around the world including in all of the top 100 global research institutions as ranked by Nature in 2020 based on publications and all of the top 20 global pharmaceutical companies by 2020 research and development spend, and have been cited in over 3,300 research papers on discoveries ranging from oncology to immunology and neuroscience. The company's patent portfolio comprises more than 1,300 issued patents and patent applications. About Element Biosciences, Inc. Element Biosciences is a multi-disciplinary life science company currently focused on developing disruptive DNA sequencing technology for research and diagnostic markets. Through innovating every fundamental element of a sequencing system, Element will empower customers with affordable high-quality data and an improved user experience, which in turn will accelerate scientific discoveries and broaden the use of genomic medicine.

Read More

CELL AND GENE THERAPY

PDS Biotech Reports An Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

PDS Biotechnology Corporation | December 27, 2021

PDS Biotechnology Corporation, a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, announced that the compensation committee of the board of directors of the Company approved, on December 20, 2021, an equity award to Michael Lalond, the Company’s new Director of Quality Assurance, as a material inducement to Mr. Lalond entering into employment with PDS Biotech. An inducement grant of 20,000 shares of PDS Biotech’s common stock, in accordance with Nasdaq Listing Rule 5635(c)(4), was awarded as part of Mr. Lalond’s compensation. The award was granted under PDS Biotech’s 2019 Inducement Plan, as amended, in accordance with Nasdaq Listing Rule 5635(c)(4) and provides for the granting of equity awards to new employees of PDS Biotech. The option award has an exercise price of $8.87, the closing price of PDS Biotech’s common stock on December 20, 2021. About PDS Biotechnology PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of cancer immunotherapies based on the Company’s proprietary Versamune® T-cell activating technology platform. Our Versamune®-based products have demonstrated the potential to overcome the limitations of current immunotherapy by inducing in vivo, large quantities of high-quality, highly potent polyfunctional tumor specific CD4+ helper and CD8+ killer T-cells.

Read More